A Phase 1b Trial of LY2584702 in Combination With Erlotinib or Everolimus in Patients With Solid Tumors.

Trial Profile

A Phase 1b Trial of LY2584702 in Combination With Erlotinib or Everolimus in Patients With Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2014

At a glance

  • Drugs LY 2584702 (Primary) ; Erlotinib; Everolimus
  • Indications Cancer; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jan 2012 Planned End Date changed from 1 Jul 2013 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 21 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Sep 2011 Planned end date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top